Short-term clinical observations of belimumab in the treatment of recently diagnosed systemic lupus erythematosus.

OBJECTIVE

To explore the therapeutic effectiveness and safety of belimumab in the treatment of recently diagnosed systemic lupus erythematosus (SLE).

METHODS

Between January 2019 and February 2022, a total of 30 patients who had been recently diagnosed with SLE were selected for 6 months of belimumab treatment at the Department of Rheumatology and Immunology, Tianjin First Central Hospital. Laboratory test results and related adverse reactions were recorded at baseline and after treatment.

RESULTS

Participants' white blood cell counts and complement 3, complement 4, and hemoglobin levels were higher after treatment than at baseline. Participants' immunoglobulin G and immunoglobulin M levels, SLE Disease Activity Index 2000 scores, glucocorticoid doses, erythrocyte sedimentation rates, and serum albumin/globulin ratios were lower after treatment. These differences were all statistically significant (p < .05).

CONCLUSION

Belimumab was safe and effective in patients recently diagnosed with SLE and might help to reduce the use of glucocorticoids and to improve anemia with few adverse reactions. Belimumab might be applied in the treatment of patients recently diagnosed with SLE with high disease activity.